ArticleScientific reports2026
Omega-3 fatty acids improve lipid metabolism by regulating miR-34a.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lipid metabolism disorders and hepatic lipid deposition are major contributors to the development of metabolic diseases such as non-alcoholic fatty liver disease. Omega-3 fatty acids have been shown to exert beneficial effects on lipid homeostasis and liver function, but their molecular regulatory mechanisms remain incompletely understood. Here, we investigated the effects of omega-3 fatty acids on lipid metabolism and hepatic lipid deposition in addition to the modulatory role of miR-34a using an in vivo high-fat diet (HFD) model and an in vitro palmitic acid (PA)-induced HepG2 cell model. We assessed the effects of omega-3 fatty acid intervention and measured lipid levels in mouse serum, triglyceride (TG) and total cholesterol (TC) levels in the mouse liver, and TG levels in HepG2 cells. Further, we evaluated the mRNA and protein levels of miR-34a, SIRT1, SREBP-1c, CPT-1 A and PGC-1α. We observed that miR-34a expression was upregulated in the HFD and PA groups. Omega-3 fatty acid intervention reduced the serum levels of TG, TC, and low-density lipoproteins(LDL-C), and decreased the levels of TG and TC in the liver tissue, alleviating hepatocyte steatosis. Further, omega-3 fatty acids intervention reduced miR-34a and SREBP-1c expression, and increased the expression of SIRT1,PGC-1α, CPT-1 A. Moreover, miR-34a overexpression inhibited the effects of omega-3 fatty acids on SIRT1, SREBP-1c, PGC-1α and CPT-1 A. Thus, omega-3 fatty acids promote lipid metabolism, thereby reducing hepatic lipid deposition by down-regulating miR-34a expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.